One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for ...

The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.

Black patients have similar immune checkpoint inhibitor (ICI) effectiveness and lower toxicities compared with White patients ...

Two of the newly discovered sequence variants with the largest effect on the risk of AITD are in a gene that codes for LAG-3 (Lymphocyte ... of immune checkpoint inhibitor therapy for cancer.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Findings published in Science Immunology resolve how human LAG-3 binds to its main ligand providing a better foundation for development of blocking LAG-3 therapeutics, including Immutep’s anti ...